Medical RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) PlatformBy Marie JonesJuly 20, 2023 RenovoRx, Inc. (“RenovoRx”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd (“Imugene”) (ASX: IMU), a clinical-stage immuno-oncology company,…
